Mindset Pharma Inc. (Mindset), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, announced that, under its Co-operative Psychedelics Evaluation Platform (COPE) program with InterVivo Solutions (InterVivo), the Company has further developed its first generation psychedelics benchmarking data by establishing standard pharmacokinetic, brain penetration, and drug discrimination data and protocols across lysergic acid diethylamide (LSD), psilocybin, and o-methyl-bufotenin (5-MeO-DMT).
The COPE Program is a translational testing platform developed in cooperation with InterVivo to introduce an industry standard against which the performance and efficacy of breakthrough psychedelic medicines are compared and assessed. Through this platform, Mindset and InterVivo intend to establish the first comprehensive psychedelics benchmark reference data set by evaluating a broad range of psychedelic drugs through a proprietary program of in vivo tests conducted at InterVivo’s facility. The COPE program is anticipated to represent an invaluable tool to guide the development of next-generation psychedelic compounds and improve patentability and value in new molecule drug assets.
Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs. Mindset was established to develop next generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs. Mindset is developing several novel families of next generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybin as well as its own proprietary compounds.
This was reported by Mindset Pharma on October 14, 2021.
Contact information: James Lanthier, Chief Executive Officer, Mindset Pharma, 217 Queen Street West, Toronto, Ontario, Canada, M5V 0R2; Email: jlanthier@mindsetpharma.com; Website: https://www.mindsetpharma.com/
